Health
Johnson & Johnson’s (JNJ) COVID-19 vaccine would have an edge over others without this glitch – AlphaStreet
Johnson & Johnson (NYSE: JNJ) saw its shares climb 2% on Thursday after the company reported positive results from the early-stage trials of its COVID-19 vaccine a day ago. The stock has gained 9% in the past three months and over 8% in the past one year. The companys vaccine candidate has an advantage over its competitors in terms of dosage and storage but this is being hindered by manufacturing issues.
Trial results
On Wednesday, the results from J&Js interim Phase 1/2a trial were published in…
-
Noosa News19 hours agoItalian Film Festival, Brisbane: All the Details
-
Noosa News15 hours agoKatter and pregnant wife crash-land plane in outback Qld
-
Business22 hours agoprofit up 7%, guidance strong
-
Noosa News14 hours agoFollowing Up Hottest 100 of Australian Songs Success with a Second Documentary About Your Life and Career: Jimmy Barnes Talks ‘Working Class Man’